Illinois SB3221 referred to Senate Assignments; bill proposes adding xylazine as a Class III controlled substance with exemptions (effective date in bill: Jan 1, 2027)

SB3221 is pending legislation that would amend the Illinois Controlled Substances Act by adding xylazine as a Class III controlled substance and making related structural changes to controlled substance lists/definitions, while carving out specified exemptions (e.g., certain veterinary/animal-drug and professional use contexts). The ILGA bill status reflects a latest action of referral to Senate Assignments (2/02/2026). The synopsis indicates a proposed effective date of January 1, 2027. Compliance teams should monitor whether xylazine becomes scheduled in Illinois, evaluate supply chain and dispensing controls, and review applicability of any exemptions for veterinary and other permitted uses.